{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:27:15Z","timestamp":1762878435888,"version":"3.45.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.euo.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T01:01:54Z","timestamp":1632272514000},"page":"464-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-4002","authenticated-orcid":false,"given":"Louis","family":"Lenfant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"The Paris system for reporting urinary cytology","author":"Rosenthal","key":"10.1016\/j.euo.2021.09.002_bib0005"},{"key":"10.1016\/j.euo.2021.09.002_bib0010","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, et al. EAU guidelines on upper urinary tract urothelial cell carcinoma. https:\/\/uroweb.org\/guideline\/upper-urinary-tract-urothelial-cell-carcinoma."},{"key":"10.1016\/j.euo.2021.09.002_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/iju.13032","article-title":"Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma","volume":"23","author":"Jinzaki","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JU.0000000000001370","article-title":"The impact of ureteroscopy following computerized tomography urography in the management of upper tract urothelial carcinoma","volume":"205","author":"Gallioli","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0025","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00345-018-2586-y","article-title":"Comparison of biopsy devices in upper tract urothelial carcinoma","volume":"37","author":"Breda","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2011.02.038","article-title":"Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management","volume":"78","author":"Smith","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.euo.2021.09.002_bib0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","article-title":"Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma","volume":"108","author":"Messer","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.002_bib0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bju.14053","article-title":"Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis","volume":"121","author":"Guo","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.002_bib0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.13935","article-title":"Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis","volume":"120","author":"Marchioni","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.002_bib0050","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000001834","article-title":"The impact of upper tract urothelial carcinoma diagnostic modality on intravesical recurrence after radical nephroureterectomy: a single institution series and updated meta-analysis","volume":"206","author":"Sharma","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0055","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00345-019-02675-0","article-title":"Which flexible ureteroscope is the best for upper tract urothelial carcinoma treatment?","volume":"37","author":"Keller","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00345-016-1859-6","article-title":"Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma","volume":"35","author":"Mandalapu","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/end.2014.0551","article-title":"Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications","volume":"29","author":"Bus","year":"2015","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2021.09.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.04.001","article-title":"Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: a prospective, single-center study","volume":"36","author":"Guo","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2021.09.002_bib0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the bladder EpiCheck methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2021.09.002_bib0080","doi-asserted-by":"crossref","first-page":"e3345","DOI":"10.1016\/S1569-9056(19)33798-4","article-title":"Feasibility of the Epicheck test in upper urinary tract tumor","volume":"18","author":"Breda","year":"2019","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2021.09.002_bib0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2021.05.004","article-title":"Pretreatment risk stratification for endoscopic kidney-sparing surgery in upper tract urothelial carcinoma: an international collaborative study","volume":"80","author":"Foerster","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.ju.0000147747.89028.64","article-title":"Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation","volume":"173","author":"Yossepowitch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0095","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2021.09.002_bib0100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eururo.2010.08.005","article-title":"Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?","volume":"58","author":"Favaretto","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0105","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1464-410X.2009.08594.x","article-title":"Laparoscopic vs open radical nephroureterectomy for upper urinary tract urothelial cancer: oncological outcomes and 5-year follow-up","volume":"104","author":"Greco","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.002_bib0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1464-410X.2010.09826.x","article-title":"Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort","volume":"108","author":"Walton","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.002_bib0115","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2009.06.013","article-title":"Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study","volume":"56","author":"Simone","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euf.2017.10.003","article-title":"Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology guidelines systematic review","volume":"5","author":"Peyronnet","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2021.09.002_bib0125","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00345-017-2026-4","article-title":"Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy","volume":"35","author":"Moschini","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/end.2020.0496","article-title":"Robotic nephroureterectomy vs laparoscopic nephroureterectomy: increased utilization, rates of lymphadenectomy, decreased morbidity robotically","volume":"35","author":"Kenigsberg","year":"2021","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2021.09.002_bib0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/end.2017.0086","article-title":"Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach","volume":"31","author":"Rodriguez","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2021.09.002_bib0145","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00345-019-03020-1","article-title":"Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases","volume":"38","author":"Veccia","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0150","article-title":"Comparison of oncological and perioperative outcomes of open, laparoscopic, and robotic nephroureterectomy approaches in patients with non-metastatic upper-tract urothelial carcinoma","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2021.09.002_bib0155","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.urology.2015.07.070","article-title":"Comparison of single-docking robotic-assisted and traditional laparoscopy for retroperitoneal lymph node dissection during nephroureterectomy with bladder cuff excision for upper-tract urothelial carcinoma","volume":"87","author":"Melquist","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.euo.2021.09.002_bib0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/end.2017.0477","article-title":"Does advancing technology improve outcomes? Comparison of the Da Vinci standard\/S\/Si to the Xi robotic platforms during robotic nephroureterectomy","volume":"32","author":"Patel","year":"2018","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2021.09.002_bib0165","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2021.09.002_bib0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2021.39.6_suppl.455","article-title":"Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)","volume":"39","author":"Birtle","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2021.09.002_bib0175","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2021.09.002_bib0180","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","article-title":"Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial)","volume":"60","author":"O\u2019Brien","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0185","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","article-title":"Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma","volume":"200","author":"Liao","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0195","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0200","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JU.0000000000000737","article-title":"Efficacy of preoperative chemotherapy for high risk upper tract urothelial carcinoma","volume":"203","author":"Foerster","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.002_bib0205","doi-asserted-by":"crossref","unstructured":"Necchi A, Martini A, Raggi D, et al. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.014.","DOI":"10.1016\/j.urolonc.2021.05.014"},{"key":"10.1016\/j.euo.2021.09.002_bib0210","doi-asserted-by":"crossref","unstructured":"Necchi A, Madison R, Pal SK, et al. Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2020.08.001.","DOI":"10.1016\/j.euf.2020.08.001"},{"key":"10.1016\/j.euo.2021.09.002_bib0215","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2021.09.002_bib0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","article-title":"Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature","volume":"78","author":"Hassler","year":"2020","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:35Z","timestamp":1762876055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931121001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2588931121001541"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2021.09.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}